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Background: Reversible ischaemia/reperfusion (I/R) liver injury has been used to induce engraftment and
hepatic parenchymal differentiation of exogenous b2-microglubulin2/Thy1+ bone marrow derived cells.
Aim: To test the ability of this method of hepatic parenchymal repopulation, theoretically applicable to clinical
practice, to correct the metabolic disorder in a rat model of congenital hyperbilirubinaemia.
Methods and results: Analysis by confocal laser microscopy of fluorescence labelled cells and by
immunohistochemistry for b2-microglubulin, 72 hours after intraportal delivery, showed engraftment of
infused cells in liver parenchyma of rats with I/R, but not in control animals with non-injured liver.
Transplantation of bone marrow derived cells obtained from GFP-transgenic rats into Lewis rats resulted in the
presence of up to 20% of GFP positive hepatocytes in I/R liver lobes after one month. The repopulation rate
was proportional to the number of transplanted cells. Infusion of GFP negative bone marrow derived cells into
GFP positive transgenic rats resulted in the appearance of GFP negative hepatocytes, suggesting that the main
mechanism underlying parenchymal repopulation was differentiation rather than cell fusion. Transplantation
of wild type bone marrow derived cells into hyperbilirubinaemic Gunn rats with deficient bilirubin conjugation
after I/R damage resulted in 30% decrease in serum bilirubin, the appearance of bilirubin conjugates in bile,
and the expression of normal UDP-glucuronyltransferase enzyme evaluated by polymerase chain reaction.
Conclusions: I/R injury induced hepatic parenchymal engraftment and differentiation into hepatocyte-like
cells of bone marrow derived cells. Transplantation of bone marrow derived cells from non-affected animals
resulted in the partial correction of hyperbilirubinaemia in the Gunn rat.
T
he pioneering work of Lagasse et al1 on the mouse with
fumarylacetoacetate hydrolase (FAH 2/2) deficiency, an
animal model of tyrosinaemia type I, has shown that bone
marrow transplantation with purified haematopoietic stem
cells from wild type animals could repopulate the liver and cure
the inherited metabolic disorder. Enthusiasm for this ther-
apeutic approach has been tempered by the finding that cell
fusion, rather than true differentiation, was responsible for
liver repopulation of cells with normal enzyme activity.2
Moreover, the metabolic defect in the FAH 2/2 mouse leads
to massive hepatocyte death, possibly creating the necessary
conditions for extensive liver repopulation with exogenous
cells. However, in most inherited disorders of liver metabolism
the metabolic defect does not lead to liver parenchymal cell
loss, and several investigators have demonstrated that in such
conditions repopulation with exogenous cells is insignificant.3
Interruption of blood flow to an organ or tissue (ischaemia)
and subsequent reperfusion leads to an acute inflammatory
response that may cause significant cellular damage.
Ischaemia/reperfusion (I/R) is a powerful stimulus for stem
cell homing and repair of the injured tissue, as demonstrated in
experimental cell therapy of myocardial infarction.4 Reversible
I/R injury of the liver has been documented in various clinical
settings, including partial liver resection (Pringle manoeuvre),
liver transplantation, and haemorrhagic shock with fluid
resuscitation. Hepatocytes are sensitive to hypoxic damage
and once injured about half the cells will undergo necrosis or
apoptosis.5
The aim of this study was to verify whether reversible I/R
injury of selected liver lobes can induce hepatic engraftment of
bone marrow derived cells, leading to further differentiation
into hepatocytes and to correction of an inherited metabolic
disorder. It is possible that such a model of reversible partial
liver injury could be applied in clinical practice to repopulate
the liver of patients with genetic liver disease with normal
exogenous liver cells, in order to correct the metabolic disorder.
METHODS
Animals
All studies with animals were conducted under protocols
approved by the Italian Ministry of Health, in accordance with
Italian law (DL 116/92). Lewis rats were obtained from Charles
River (Wilmington, Massachusetts, USA). Transgenic rats
carrying enhanced green fluorescent protein (GFP) were a kind
gift from Dr Masaru Okabe, Osaka, Japan. These animals
express enhanced GFP as non-secreted cytoplasmic protein
throughout the body except in peripheral erythrocytes and
hair.6 Jaundiced Gunn (JJ) rats and the non-hyperbilirubinae-
mic wild type (++, HSD:WT) were from Harlan, Indianapolis,
Indiana, USA.
Isolation of bone marrow derived cells
b2-Microglobulin (b2m)2/(Thy-1)
+ cells (from now on referred
to as bone marrow derived cells (BMDCs)) were isolated using
a two step magnetic bead cell sorting method, as previously
described.7
Ischaemia/reperfusion injury
Laparotomy was carried out under pentobarbitone (pentobar-
bital) anaesthesia (60 mg/kg). The animal was given 10 IU
heparin intravenously and the blood supply to the right lobe of
Abbreviations: b2m, b2-microglobulin; BMDC, bone marrow derived cell;
DAPI, 49,6-diamidino-2-phenylindole; FAH, fumarylacetoacetate
hydrolase; GFP, green fluorescent protein; I/R, ischaemia/reperfusion; JJ,
jaundiced Gunn
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the liver (corresponding to about 30% of total liver mass) was
occluded with an atraumatic vascular clamp for 60 minutes.
The body temperature was maintained at 37¡0.3 C˚ by a
heating lamp. Reperfusion was initiated by removal of the
clamp. Under these experimental conditions, a significant
increase in necrotic and apoptotic hepatocytes is observed one
hour after reperfusion.5 The animals received 1 ml of sterile
saline intraperitoneally, the wound was closed in layers with 4-
0 silk and wound staples, and the rats were allowed to recover.
Twenty four hours after reperfusion, the animals were re-
anaesthetised, the abdomen reopened, and BMDCs suspended
in 0.9% saline solution were seeded in the test animals through
the portal vein into the right lobe of the liver. Control rats
received saline solution alone.
Evaluation of liver parenchymal repopulation
The degree of hepatic engraftment achieved was monitored by
two different criteria: fluorescent staining of BMDCs with a
membrane bound dye, and genetic labelling (GFP-transgenic
animals). A description of the experimental groups is given in
table 1.
Fluorescent staining of BMDCs
BMDCs were stained with PKH26 red fluorescent cell linker (6
mmol/l). Three experimental groups of Lewis inbred male rats
were studied: group A (n = 9), animals with intraportal infusion
of 56106 BMDCs in the absence of I/R injury; group B (n = 16),
animals with intraportal infusion of BMDCs following I/R
injury; group C (n = 6), animals with I/R injury without BMDCs
infusion.
GFP labelled cells
Two different experimental protocols were used:
First series (GFP posit ive cells into GFP negative animals)
BMDCs were isolated from GFP positive transgenic rats and
transplanted into Lewis rats. This series included four experi-
mental groups: group D (n = 5), rats with I/R injury and
transplantation of 76106 BMDCs, and control group E (n = 3),
rats with I/R injury without cell transplantation (both groups
were studied 72 hours after cell infusion). Group F (n = 7), rats
with I/R injury and transplantation of different amounts of
BMDCs (16106, n = 2; 76106, n = 3; and 106106, n = 2,
respectively) and control group G (n = 6), rats with I/R injury
without cell transplantation. In group F, two female rats
received 106106 BMDCs isolated from male animals, in order to
use the Y chromosome as a second independent marker of
transplanted cells. Both group F and group G were studied one
month after cell infusion. All animals received daily immuno-
suppressive treatment with ciclosporine A, 15 mg/kg.
Second series (GFP negative cells into GFP posit ive animals)
To evaluate the occurrence of fusion, 76106 GFP negative
BMDCs were infused into each GFP positive animal following I/
R (group H, n = 6), while controls received vehicle only (group I;
n = 4). In these conditions, differentiation of BMDCs should
produce GFP negative hepatocytes, while fusion between
haematopoietic cell lineages and liver parenchymal cells should
result in GFP positive hepatocytes. The animals were studied
one month after cell infusion. All animals received daily
immunosuppressive treatment with ciclosporine A, 15 mg/kg.
Collection of samples
The animals were killed by exsanguination under anaesthesia
and liver samples were collected from the postischaemic and
the non-ischaemic lobes. Samples were either fixed in
phosphate buffered formalin for immunohistochemical analy-
sis or frozen in dry ice and stored at 280 C˚ until fluorescent
microscopy analysis.
Histology, immunohistochemistry, and FISH
Liver tissue was fixed in 10% formalin and embedded in
paraffin. Sections 5 mm thick were cut and stained with
haematoxylin-eosin for morphological analysis and for count-
ing the fluorescent stained cells. Immunohistochemistry was
undertaken with antibodies against b2m (Santa Cruz, Santa
Cruz, California, USA), GFP (Abcam, Cambridge, UK), or CK18
(Progen, Heidelberg, Germany). Fluorescent stained cells were
analysed using confocal laser microscopy. At least 500
hepatocytes were counted per animal, and the number of
fluorescent cells was expressed as per cent of counted
hepatocytes. Tissue sections were deparaffinised, rehydrated,
and either treated for 15–20 minutes at room temperature with
0.06% Triton X-100 and 0.1% H2O2 for b2m and GFP antibodies,
or microwaved at 750 W for 10 minutes in 10 mM citrate
buffer, pH 6.0, for CK18 antibody, and cooled down for at least
45 minutes. After washing in phosphate buffered saline (PBS),
sections were incubated with normal serum in PBS for one
hour at room temperature and for 30 minutes in an avidin/
biotin blocking kit (Vector, Vinci-Biochem, Firenze, Italy).
Sections were then incubated with the primary antibodies for
two hours at 37 C˚ (b2m 1:20; CK18 1:20) or for one hour at
Table 1 Summary of experimental groups
Group Procedure Harvest n
Cell tracking with fluorescent dye Transplantation of fluorescent labelled BMDCs (PKH26)
A 56106 BMDCs ip in the absence of I/R injury 72 h 9
B 56106 BMDCs ip after I/R injury 72 h 16
C Vehicle only after I/R injury 72 h 6
Cell tracking with GFP and Y chromosome Transplantation of GFP positive BMDCs
D 76106 BMDCs after I/R injury 72 h 5
E vehicle only after I/R injury 72 h 3
F 16106, 76106, and 106106 BMDCs after I/R injury 1 m 7
G Vehicle only after I/R injury 1 m 6
Investigating cell fusion Transplantation of BMDCs from wild type into GFP positive rats
H 76106 BMDCs after I/R injury 1 m 6
I Vehicle only after I/R injury 1 m 4
Assessing liver specific metabolic function in vivo Transplantation of BMDCs from wild type into Gunn rats
K 106106 BMDCs after I/R injury 1 m 6
L Vehicle only after I/R injury 1 m 6
BMDC, bone marrow derived cell; GFP, green fluorescent protein; ip, intraportal; I/R, ischaemia/reperfusion.
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room temperature (GFP 1:1200). The biotin conjugated
secondary antibody was applied followed by incubation with
peroxidase-streptavidin reagent, both for 30 minutes at room
temperature (peroxidase vectastain elite ABC kit universal for
GFP and CK18; peroxidase vectastain ABC kit, goat IgG, for
b2m (Vector, Vinci-Biochem)). The immunoreaction was
visualised by developing sections with diaminobenzidine
(Dako Cytomation, Milan, Italy). Controls consisted of incuba-
tion with normal serum instead of the primary antibody and of
tissue sections expressing or not the specific antigens.
Dual staining protocol GFP/b2m
The anti-GFP antibody was detected by biotin labelled swine
anti-rabbit (1:400, Dako, Glostrup, Denmark) after avidin/
biotin and serum blocking, followed by streptavidin-alkaline
phosphatase (1:50, Dako) and visualisation with Alexa 488
(Invitrogen, Paisley, UK). The goat polyclonal anti-b2m anti-
body (1:20) was used after avidin/biotin and protein blocking
followed by donkey anti-goat labelling with vector red (Vector
Labs, Burlingame, California, USA). DAPI (49,6-diamidino-2-
phenylindole) counterstaining was carried out before mounting.
Dual staining protocol, GFP/albumin
The polyclonal rabbit anti-albumin antibody (1:2000, Dako)
was used, after the blocking steps, followed by biotin labelled
swine anti-rabbit, streptavidin-alkaline phosphatase, and vec-
tor red development, as above. Following multiple washing
steps and blocking with avidin/biotin and total protein block
(Dako) the GFP antibody was applied (with PBS/normal goat
serum) followed by goat anti-rabbit Alexa 488 (Invitrogen).
DAPI counterstaining was carried out as above.
At least 500 hepatocytes were counted at high power field
(2006), and the presence of BMDC derived hepatocyte-like
cells (GFP positive or negative) was confirmed by examination
at 4006. The number of BMDC derived hepatocyte-like cells
was expressed as per cent of total counted hepatocytes.
The bone marrow origin of hepatocyte-like cells was
confirmed by fluorescent in situ hybridisation (FISH) for the
Y chromosome using a rat Y/12 chromosomal paint (Y-Cy3; 12-
FITC, CA-1631, Cambio, Cambridge, UK) combined with
immunohistochemistry for GFP. Sections were dewaxed and
then microwaved for 10 minutes in sodium citrate (2.94 g/l).
The primary antibody was an anti-GFP (1:500) (catalogue No
Figure 1 Identification of b2-
microgroglubilin (b2m) negative cells in liver
sections 72 hours after intraportal infusion of
bone marrow derived cells (BMDCs). Liver
sections from a control animal without
ischaemia/reperfusion (I/R) injury (group
A). (A) Typical appearance at confocal
microscopy of a fluorescence labelled cell in
non-injured liver parenchyma. (B) At
immunohistochemistry for b2m a small cell
with ovoid nucleus, condensed chromatin,
and a small rim of b2m negative cytoplasm is
visible inside a liver sinusoid (arrow). Liver
sections from animals with I/R injury (group
B). (C) Typical appearance at confocal
microscopy of a fluorescence labelled cell in
injured liver parenchyma. (D) (E) (F) At
immunohistochemistry, b2m negative cells
with smaller nuclei than the surrounding
hepatocytes are integrated within liver
parenchyma; nuclear chromatin looks less
condensed than in group A (arrowheads)
and the cells acquire a polygonal shape with
a large cytoplasm. (Original magnification:
(A), (B) 6100; (C), (D), (E), (F)640.)
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A11122, Molecular Probes, Eugene, Oregon, USA) and the
secondary antibody was an Alexa Fluor 647-anti-rabbit
(Molecular Probes). Sections were incubated in 1 M sodium
thiocyanate for 10 minutes at 80 C˚, washed in PBS, and then
digested in pepsin (0.4% wt/vol) in 0.1 M HCl, at 37 C˚ for four
minutes. After quenching in glycine (0.2% vol/wt), the sections
were rinsed in PBS, post-fixed in paraformaldehyde (4% wt/
vol), dehydrated through graded alcohols, and air dried. The
chromosome paints were added to the sections, sealed under
glass with rubber cement, heated to 60 C˚ for 10 minutes, and
incubated overnight at 37 C˚. The slides were rinsed in 0.56SSC
(NaCl/sodium citrate) and then in PBS and mounted in
Vectashield (Vector Laboratories) for confocal microscopy.
Correction of the metabolic disorder in the Gunn rat
Gunn j/j rats with congenital deficiency of bilirubin glucur-
onyltransferase were subjected to I/R injury. Forty eight hours
after the procedure, the animals received an intraportal
infusion of either 106106 BMDCs isolated from wild type
syngeneic animals (group K, n = 6) or saline solution (group L,
n = 6). Blood was collected from the tail vein before surgery
and 30 days after cells infusion. After 30 days, the animals were
anaesthetised and bile was collected on ice and in the dark.
Alkaline methanolysis—HPLC analysis of bile pigments in bile
and plasma—was carried out as described previously.8 Liver
tissue was obtained for RNA extraction as described below.
RNA extraction and PCR analysis
Total RNA was extracted from snap frozen liver tissue using Tri
Reagent solution (Sigma-Aldrich, Milan, Italy), according to
the manufacturer’s instructions. One microgram of total RNA
was reverse transcribed with Moloney murine leukaemia virus
reverse transcriptase (2.5 U/ml) in a final volume of 20 ml
containing: buffer (500 mmol/l KCL, 100 mmol/l Tris-HCl,
pH 8.3), MgCl2 (5 mmol/l), dNTPs (1 mmol/l), random exam-
ers (2.5 mmol/l), and RNase inhibitor (1 U/ml). After an
incubation period of 10 minutes at room temperature, the
cDNA synthesis was carried out in a thermalcycler (Perkin
Elmer, Milan, Italy) for 30 minutes at 42 C˚.
Polymerase chain reaction (PCR) was carried out using the
following specific primers that amplified a 600 base pair (bp)
fragment of the sequence of rat UGT1A1, the only uridine
diphosphate glucoronosyltransferase isoform that preferentially
binds bilirubin: UGT1A1 forward 59-GAA AGA TTA CCC CAG
GCC CAT CAT GCC-39; UGT1A1 reverse 59-GCC AGG TCC AGA
GGC TCG ATA GGA CG-39. The specificity and efficiency of the
PCR reaction was increased using the Eppendorf HotMasterMix
(Eppendorf, Milan, Italy), according to the manufacturer’s
instructions. The cycle employed was: two minutes at 94 C˚, 38
cycles of one minute at 95 ,˚ 40 seconds at 58 C˚, and 40 seconds
at 72 C˚, followed by seven minutes at 72 C˚, before ending at
4 C˚. PCR products were digested with MvaI (Roche Diagnostics,
Monza, Milan, Italy) and analysed on 7% acrylamide gel,
visualised by ethidium bromide and then silver stained.
Statistical analysis
Analyses were done using the Mann–Whitney test (two tailed)
and the correlation analysis in the GraphPad Prism software
program (San Diego, California, USA).
RESULTS
PKH26 labelled BMDCs
More fluorescent cells were observed in livers of group B (rats
that underwent I/R) than of sham operated group A rats (mean
(SD): 0.28 (0.11) vs 0.04 (0.01) PKH26 labelled cells/100
hepatocytes; p,0.0001; fig 1). Immunohistochemistry for b2m
showed the presence of b2m negative cells integrated in the
liver parenchyma of I/R rats and having morphological features
of hepatocyte differentiation (group B, fig 1). A few b2m
negative cells were occasionally observed in sinusoidal spaces.
In group A, as well as in non-ischaemic liver lobes of group B,
small b2m cells were sporadically observed only inside portal
branches or sinusoids (fig 1). No b2m negative cells were
observed in the non-infused controls (group C).
GFP labelled BMDCs
At immunohistochemistry, GFP was homogeneously expressed
in liver parenchymal cells of transgenic animals. Seventy two
hours after transplantation, GFP positive, CK18 positive
hepatocyte-like cells were found in ischaemic lobes of Lewis
rats with I/R at a frequency of 0.39 (0.31) (n = 5), as per cent of
total hepatocytes in the liver (group D; fig 2, panels A, B, C, D),
while no GFP positive cells were present in controls without cell
infusion (group E). The frequency of repopulation at 72 hours
with GFP labelled hepatocytes was comparable to that observed
with PKH26 labelled cells (group A, 0.28 (0.11); group D, 0.39
(0.31); p.0.05). Immunofluorescence analysis showed that
after 72 hours some GFP positive cells stained negative for b2m
(fig 3D). The extent of repopulation with GFP positive
hepatocyte-like cells was further evaluated one month after
transplantation (group F), and was found to be proportional to
the number of infused cells (linear regression: r2 = 0.9117;
exponential growth: R2 = 0.9575; fig 4), up to approximately
20% of total liver parenchymal cells after infusion of 106106
BMDCs (fig 5, panels A to E). Immunofluorescence analysis
showed that GFP positive hepatocyte-like (bone marrow
derived) cells stained more weakly for albumin than the
surrounding native hepatocytes (fig 6). GFP positive endothe-
lial-like cells were also observed in the ischaemic lobes of Lewis
rats one month after transplantation, while they were not
found in non-ischaemic parenchyma (fig 5F). The use of a
double marker (that is, FISH for Y chromosome and co-staining
with anti-GFP antibody) further confirmed the bone marrow
origin of the GFP positive liver parenchymal cells. Liver
parenchyma of female rats receiving male BMDCs showed the
presence of clusters of GFP positive hepatocytes incorporating
the Y chromosome (fig 7). Again, no GFP positive cells were
present in controls without cell infusion (group G). Infusion of
BMDCs isolated from Lewis rats into GFP-transgenic rats was
associated with the appearance of GFP negative, CK18 positive
hepatocytes (group H, fig 8), while no GFP negative hepato-
cytes were observed in controls (group I). The proportion of
repopulation of GFP negative hepatocytes in GFP positive livers
infused with 76106 BMDCs was 5.38 (1.49)%, and it was not
significantly different from the percentage of GFP positive
hepatocytes observed in GFP negative livers infused with the
same quantity of cells (8.2 (1.9)%).
Gunn rats
Analysis of blood and bile bilirubin concentrations
Thirty days after cell transplantation, the level of plasma
unconjugated bilirubin was 35% lower than in basal conditions
in rats receiving cell infusions (group K), while it was
unchanged in control animals (group L) (fig 9). The decrease
in plasma bilirubin was associated with the appearance of
monoconjugated bilirubin in bile (0.9 (0.19) mmol/l; n = 6),
while no conjugates were detected in controls (fig 10). The
alkaline methanolysis procedure adds specificity to the identi-
fication of bilirubin conjugates, as the trans-esterification
reaction yielding bilirubin methylesters from bilirubin glucur-
onides takes place only in an alkaline environment. When plain
methanol was substituted for alkaline methanol, the peak of
bilirubin monomethylesters was selectively absent from the
chromatogram. Such verification confirmed the presence of
1728 Muraca, Ferraresso, Vilei, et al
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bilirubin conjugates in the Gunn rats transplanted with
BMDCs.
PCR analysis
PCR analysis of uridine diphosphate glucoronosyltransferase
(UDP-GTA) gene expression followed by digestion with the
restriction enzyme MvaI is illustrated in fig 11. The amplifica-
tion product of the normal donor cDNA yields four bands (12,
67, 123, and 384 bp) after digestion. As the 12 bp band is lost
during chromatography, only three bands are visible. The PCR
product of Gunn rat cDNA lacks a restriction site on position
1271 for this enzyme, and therefore the digestion products yield
Figure 2 Bone marrow derived cells
(BMDCs) isolated from green fluorescent
protein (GFP) positive rats acquire
morphological features and phenotypic
markers of differentiated hepatocytes after
transplantation into liver injured Lewis
recipients (group D). Serial sections of livers
removed 72 hours after cell transplantation
were stained for GFP (A) (C) and for CK-18
(B) (D). GFP positive cells are also positive for
the epithelial marker CK-18. Several GFP
positive cells with hepatocyte-like
morphology are visible. The arrow indicates
a binucleated cell, a feature typical of
hepatocytes. Some GFP positive cells are
smaller and have smaller nuclei
(arrowheads) than the surrounding host
hepatocytes. (Original magnification 640.)
The two figures in the lower panel are: (E) a
liver section from a Lewis rat (group E, GFP
negative control) and (F) a liver section from
a GFP-transgenic animal (GFP positive
control), respectively. (Original
magnification610.)
Figure 3 Sections of livers removed 72
hours after cell transplantation (group D)
were stained for GFP (A, fluorescent green)
and b2m (B, fluorescent red) combined with
DAPI nuclear staining (C, fluorescent blue).
Some smaller (presumably less
differentiated) GFP positive cells stain
negative for b2m (arrow) while some larger
(presumably more differentiated) GFP
positive cells stain positive (arrowhead) (D).
Stem cell therapy of congenital hyperbilirubinaemia 1729
www.gutjnl.com
three bands (511, 67, and 12 bp, the last one not visible). In
Gunn j/j rats, which received infusion of BMDCs from non-
affected, wild type animals, four bands are visible, including
those derived from digestion of the normal enzyme.
DISCUSSION
There has been much interest in cell therapy for liver metabolic
disorders in the last decade, and several investigators have
reported a significant clinical improvement following hepato-
cyte transplantation as an alternative to liver transplantation.9
Major limitations are the limited availability of human
hepatocytes and the limited long term efficacy. In theory, the
use of BMDCs as an alternative to hepatocytes could solve both
problems. The present work indicates first, that a significant
parenchymal repopulation with hepatocyte-like cells derived
from BMDCs can be induced even in metabolic disorders not
associated with increased parenchymal cell turnover; second,
that probably such repopulation is mostly due to differentiation
rather than to cell fusion; and third, that such repopulation
results in partial correction of a congenital hepatic metabolic
disorder.
The extent of parenchymal repopulation with exogenous
bone marrow derived, GFP positive hepatocyte-like cells
averaged 0.4% in the liver lobes submitted to I/R 72 hours
after infusion, but it increased by more than 20-fold after one
month, suggesting proliferation of the exogenous cells. The
histological finding showing large clusters of GFP positive
hepatocytes supports this hypothesis. Continuous propagation
of stem/progenitor cells in the absence of ongoing liver damage
can be driven by cell–cell competition, with increased prolifera-
tion and reduced apoptosis of the transplanted cells when
Figure 4 Percentage of green fluorescent protein (GFP) positive
hepatocytes (Hcs) one month after GFP positive bone marrow derived cell
(BMDC) transplantation, as a function of the number of infused cells (group
F; n = 8).
Figure 5 Bone marrow derived cells
(BMDCs) isolated from green fluorescent
protein (GFP) positive transgenic rats acquire
morphological features and phenotypic
markers of differentiated hepatocytes after
transplantation into liver injured Lewis
recipients (group F). Serial sections of livers
removed four weeks after cell transplantation
were stained for GFP (A) and for CK-18 (B).
(C–E) Extensive repopulation of liver
parenchyma with GFP positive hepatocyte-
like cells four weeks after transplantation of
106106 GFP positive BMDCs (group F).
Large clusters of GFP positive hepatocyte-like
cells are mainly located in proximity of blood
vessels. (F) GFP positive endothelial-like cells
(arrows) are also visible in the ischaemic
lobes. (Original magnification: (A), (B)620;
(C), (D), (E)610; (F)640.)
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compared with host hepatocytes.10 Previous work reported low
or insignificant repopulation in several animal models of liver
injury,3 11 with the notable exception of a study by Jang et al,12
which demonstrated 7.6% repopulation 48 hours after cell
infusion. Possible explanations for such differences include the
selected stem cell population, the model of liver damage (also
involving the endothelium), direct intraportal infusion vs
systemic administration, and the survival advantage of trans-
planted cells in a milieu of endogenous cells injured by the
previous I/R injury.
Figure 6 Sections of livers removed one
month after cell transplantation (group F)
were stained for green fluorescent protein
(GFP) (A, fluorescent green) and albumin (B,
fluorescent red) combined with DAPI nuclear
staining (C, fluorescent blue). GFP positive
(bone marrow derived) hepatocyte-like cells
stain more weakly or negatively for albumin
when compared with the surrounding
autologous (GFP negative) hepatocytes (D).
Figure 7 Confocal microscopy analysis of liver tissue of a female rat one month after infusion of bone marrow derived cells (BMDCs) isolated from male
GFP-transgenic rats (A) (B). Tissue has been processed with fluorescent in situ hybridisation (FISH) for the Y chromosome (Cy3, red nuclear signals) and
immunostained for GFP (Cy5 labelling, blue cytoplasmic stain). Nuclei are dark as there is no nuclear DAPI labelling. Clusters of GFP positive hepatocytes
incorporating the Y chromosome signal are visible throughout the parenchyma (606); interestingly there are frequently multiple Y signals in a nucleus,
denoting polyploidisation, a typical hepatocyte feature. (B) An enlarged section of the area indicated by an asterisk (*) in the panel (A). (C, D) Fluorescent
microscopy of control liver tissue: here DAPI (blue) is used to label the nuclei as no cytoplasmic fluorochrome is used; again Y chromosome detection is with
the Cy3 labelled chromosome paint (red). (C) Male control liver shows nuclear Y chromosome labelling (red signals). (D) Female control livers have no
nuclear Y chromosome labelling.
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The infused BMDC population7 13 was selected on the basis of
negativity for b2m and of positivity for Thy-1, a haematopoietic
stem cell marker shared by hepatic oval cells. b2m participates
as an integral part in molecules of the major histocompatibility
complex (MHC I).14 Indeed, BMDCs share MHC I negativity.15
Fetal hepatoblasts16 as well as neuronal stem cells17 are negative
for MHC class I antigens, suggesting that such a feature could
be a general marker of stemness/immaturity. A subpopulation
of b2m negative BMDCs was shown to differentiate into
cardiomyocytes and to reconstitute the myocardium in a model
of myocardial infarction.18 Interestingly, b2m negative cells
appeared to be selected (or b2m downregulated) following
transplantation of human cord blood stem cells in the liver of
SCID mice.19 More recently, a population of b2m negative, c-
Met positive cells was shown to differentiate into hepatocyte-
like cells in culture.20 That b2m negative cells are the true
population responsible for the liver parenchymal repopulation
in the present work is suggested by the presence of b2m
negative cells integrating in liver parenchyma and showing
morphological signs of hepatocytic differentiation 72 hours
after infusion (fig 1).
I/R is a powerful stimulus for stem cell homing and repair of
the injured tissue, probably mediated through the rapid
induction of the stem cell factor in various tissues, including
the myocardium,4 the retina,21 and the liver.22 Moreover,
macrophage activation secondary to the ischaemic damage is
associated with the release of cytokines, activating endothelial
cells with release of adhesion molecules, facilitating the
anchorage and translocation of circulating stem cells.23 24
Ischaemic damage is also associated with the induction of
SDF-1, a key molecule in stem cell recruitment to injured
organs and tissues.25 In addition, the endothelial damage
associated with I/R injury might facilitate translocation and
Figure 8 Immunohistochemistry (IHC) on
serial sections for green fluorescent protein
(GFP) (A) (C) (E) and for CK-18 (B) (D) (F)
one month after infusion of GFP negative
bone marrow derived cells (BMSC) into GFP
positive transgenic rats (group H). Animals
were subjected to hepatic ischaemia/
reperfusion (I/R) injury before cell infusion.
Several GFP negative (arrows), CK-18
positive hepatocytes are visible within the
liver parenchyma, suggesting differentiation
from GFP negative BMDCs into hepatocyte-
like cells rather than cell fusion between
BMDCs and host hepatocytes. (Original
magnification: (A), (B) 620; (C), (D), (E), (F)
640.)
Figure 9 Serum bilirubin immediately before and 30 days after bone
marrow derived cell (BMDC) transplantation in Gunn rats. Black bars
represent animals transplanted with 106106 BMDCs from wild type non-
jaundiced rats. Controls (white bars) received vehicle only. Data are
expressed as means, error bars = standard deviation, n = 6. * Different from
basal conditions, p,0.05.
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parenchymal engraftment of infused cells.26 Indeed, BMDCs
were invariably observed only within the blood vessels 72 hours
after infusion into normal livers, while engraftment of b2m
negative cells was evident at the same time in I/R injured livers
(figs 1 and 3).
In pilot experiments, we did not observe significant homing
of fluorescent labelled BMDCs when the cells were adminis-
tered immediately after releasing the vascular clamps. Thus the
activation of biochemical signals was necessary in order to
induce homing and engraftment of BMDCs.
Previous studies demonstrating insignificant liver parenchy-
mal repopulation with BMDCs involved either bone marrow
transplantation with subsequent random migration to the liver
of an unknown cell population3 9 or the intravenous systemic
delivery of a selected cell phenotype.27 As the behaviour of stem
cells is strongly determined by their niche,28 direct intraportal
infusion of BMDCs might have contributed to the relatively
high hepatic repopulation with bone marrow derived hepato-
cytes observed in the present study. The importance of the local
concentration of transplanted cells is also supported by the
finding of a positive relation between the number of adminis-
tered cells and the extent of parenchymal repopulation (fig 4).
Studies with hepatocyte transplantation have shown that a
metabolic liver deficiency can be corrected by transplanting as
little as 2% of the total hepatocyte mass, 25–50% of which will
probably engraft.24 According to our results in group F,
transplantation of 106106 BMDCs results in 20% repopulation
of the infused lobes, corresponding to about 30% of the total
liver mass. Therefore the magnitude of the repopulation relative
to the whole liver is about 6–7%. Such parenchymal repopula-
tion with hepatocytes derived from healthy BMDCs was able to
partially correct a metabolic liver disease, as demonstrated by
the decrease in serum bilirubin associated with the appearance
of conjugated bilirubin in the bile of Gunn rats. The metabolic
improvement was relatively small when compared with
previous reports on hepatocyte transplantation, where a similar
repopulation rate with exogenous wild type hepatocytes in
Gunn rats resulted in up to a 50% decrease in blood
bilirubin.29 30 Clinical hepatocyte transplantation followed by
phenobarbitone (phenobarbital) treatment in a girl with
Crigler–Najjar disease produced a 32% decrease in serum
bilirubin.31 Collectively, these results confirm that even the
appearance of a low metabolic activity can produce dramatic
changes in serum bilirubin levels.
Our results do not exclude a fusion process2 32 33 as a possible
mechanism partially contributing to the observed repopulation
of liver parenchyma with ‘‘normal’’ hepatocytes. However, the
extent of liver parenchymal repopulation with exogenous cells
was similar in the GFP positive to GFP negative and in the GFP
negative to GFP positive groups. Moreover, fusion was
Figure 10 Alkaline methanolysis-HPLC
analysis of bilirubin pigments in bile. (A) Bile
from a wild type non-jaundiced rat. (B) Bile
from a j/j (jaundiced) Gunn rat. (C) Bile from
a j/j Gunn rat one month after
transplantation with bone marrow derived
cells (BMDCs) from wild type animals. (D)
When plain methanol was substituted for
alkaline methanol in the above bile sample,
the peak of bilirubin monomethylesters was
selectively absent from the chromatogram,
confirming its derivation from bilirubin
monoglucoronide (see Results). BDC,
bilirubin diconjugate; BMC, bilirubin
monoconjugate; HPLC, high performance
liquid chromatography; IS, internal
standard; UCB, unconjugated bilirubin.
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described as a late phenomenon,2 32 33 while in the present
study, evidence of hepatocytic differentiation of BMDCs was
observed already 72 hours after infusion (figs 1 and 2), as in the
observations reported by Jang et al in liver injured mice.12 More
recent work further supports the hypothesis that, through
subjection to local growth factors and cell–cell contact, the
BMDCs may undergo changes in cell fate, mimicking the
phenotype of the surrounding cells in the absence of cell
fusion.34 Interestingly, the BMDCs had high levels of CK-18
expression, similar to oval cells.35 However, the expression of
albumin was lower than in the surrounding indigenous non-
bone-marrow derived hepatocytes (fig 6), suggesting that these
hepatocyte-like cells were less metabolically competent, in
keeping with a lower than expected metabolic effect in the
Gunn rat.
A limitation of the present study is the short observation
period following the metabolic improvement in treated
animals. Even if exogenously derived cells showed normal
appearance at histology one month after transplantation of
BMDCs, we cannot exclude the possibility that longer observa-
tion times would result in improved expression of metabolic
activity. Another important issue is the life span of transplanted
cells, as loss of the metabolic effect over time has been observed
in clinical hepatocyte transplantation.3 Clearly, much longer
observation times would be required to answer these questions.
Conclusions
We achieved partial correction of a genetic liver metabolic
disorder in a rat model by reversible I/R injury followed by
transplantation of BMDCs, which differentiated into hepato-
cyte-like cells and showed specific (although lower than
expected) metabolic activity. These results provide preliminary
proof-of-principle that such a procedure could be used as a
therapeutic tool in patients with inherited disorders of liver
metabolism.
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